PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93024C00019Nanovaccine for eliciting BNABS against hiv-1 — Neovaxsyn Inc

Neovaxsyn Inc holds $2.3M across 4 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 2 offers. Set-aside status: SBA. Recompete timing centers on the Jun 30, 2028 PoP end — agencies typically plan 12–18 months ahead.

National Institutes Of Health Niaid

Awarding office

Neovaxsyn Inc

Recipient

Jun 30, 2028

PoP end

$2M

Obligated

$2M

Potential

541715

NAICS

AN12

PSC

SBA

Set-aside

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Neovaxsyn Inc — $90

Contract facts

SBA

Contract number75N93024C00019

AgencyNational Institutes Of Health Niaid

Awarding officeNational Institutes Of Health Niaid

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentNeovaxsyn Inc

CAGE7RK00

UEIEHMTBALCKFE8

NAICS541715

PSCAN12

Place of performanceAMES IA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition After Exclusion Of Sources

Related solicitationSBIRPHS20201

PoP startJul 1, 2024

PoP end (current)Jun 30, 2028

Obligated$2M

Current value$2M

Potential value$2M

NANOVACCINE FOR ELICITING BNABS AGAINST HIV-1 is a federal SBA award for National Institutes Of Health Niaid held by Neovaxsyn Inc. Estimated value $2M ($2M obligated). Current period of performance ends Jun 30, 2028. Last award drew 2 bidders. Place of performance: AMES IA. Related solicitation SBIRPHS20201.

NANOVACCINE FOR ELICITING BNABS AGAINST HIV-1

Recompete timing

Public

● Expiring in 662 days

Current PoP ends Jun 30, 2028 (662 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Dec 30, 2026.

Incumbent footprint

Public record

Neovaxsyn Inc — $2.3M obligated across 4 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$2.3M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N93024C00019?

75N93024C00019 (Nanovaccine for eliciting BNABS against hiv-1) is a National Institutes Of Health Niaid award with a potential value of $2M, currently held by Neovaxsyn Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N93024C00019?

National Institutes Of Health Niaid awarded 75N93024C00019 to Neovaxsyn Inc (potential $2M).

Who is the incumbent on 75N93024C00019?

Neovaxsyn Inc is the incumbent with $2.3M across 4 related awards in SCOUT’s public footprint. The current period of performance ends Jun 30, 2028.

When does Neovaxsyn Inc’s 75N93024C00019 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 30, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N93024C00019 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jun 25, 2026